# of Displayed Technologies: 1 / 1

Applied Category Filter (Click To Remove): Blood & Lymphatic Disease


Categories

Targeting EGFL7 in AML
TS-037353 — Treatment of blood cancer with anti-EGFL7 antibody.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival is only 30-40% in younger (<60 years) and <10% in older adult AML patients. This highlights the urgent need for novel therapeutic approaches for a…
  • College: College of Medicine (COM)
  • Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
  • Licensing Officer: Ezzell, Janel

Loading icon